Abstracts tagged "Bone density"

Abstract Number: 0115 • ACR Convergence 2020
Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project
Khiem Vu¹, Chima Ohadugha¹, Kevin Dao¹, Rabih Nayfe² and Andrew Mangano¹, ¹Grand Strand Medical Center, Myrtle Beach, SC, ²Carolina Health Specialists - Rheumatology, Myrtle Beach, SC
Background/Purpose: There are known indications for osteoporosis screening in women. However, osteoporosis also occurs in men and fragility fractures are linked to increased morbidity and…
Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
JB Boone¹, S. Bobo Tanner ¹ and April Barnado ¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…
Abstract Number: 2212 • 2019 ACR/ARP Annual Meeting
Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA
Dalit Ashany¹, Susan Goodman ², Haley Tornberg ¹, Donald McMahon ³, Douglas Mintz ⁴, Linda Russell ⁵ and Emily Stein ¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ³Donald J.McMahon Statistical Consulting, South Nyack, NY, ⁴Hospital for Special Surgery, Division of Radiology and Imaging, New York, ⁵Hospital for Special Surgery, New York
Background/Purpose: Axial Spondyloarthritis (axSpA) is characterized by abnormal bone formation that produces syndesmophytes, while paradoxically, inflammation causes increased bone resorption and skeletal fragility. Detection of…
Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Ikuko Tanaka¹, Mari Ushikubo ², Misako Konishi ², Yutaro Hayashi ², Satoshi Hama ³, Keisuke Izumi ², Yutaka Okano ², Shigenori Tamaki ⁴ and Hisaji Ohshima ², ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Tokyo Medical Center, Tokyo, Japan, ³tokyo medical center, tokyo, Japan, ⁴Nagoya Rheumatology Clinic, Nagoya, Japan
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
Abstract Number: 2222 • 2019 ACR/ARP Annual Meeting
Bone Health: An Independent Predictor of Coronary Artery Disease
Lilian Bizzocchi¹, Maria Salgado ¹, Bhavin Chokshi ¹, Navneet Kaur ¹, Oscar Mena ¹ and Michal Packman ², ¹Jacobi Medical Center, Bronx, NY, ²North Central Bronx Hospital, Bronx, NY
Background/Purpose: An association between low bone mineral density (BMD) and cardiovascular events has been shown. The calcification process observed in atherosclerosis and bone mineralization have…
Abstract Number: 2228 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients
Katherine Wysham¹, Jonathan Graf ², Jane Shofer ³, Dennis Black ², James Andrews ³, Dolores Shoback ² and Patricia Katz ², ¹Veterans Health Administration Puget Sound, Seattle WA, Seattle, ²University of California, San Francisco, San Francisco, CA, ³University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an independent risk factor for osteoporosis (OP) and fracture. Although several OP risk factors are well-described in RA, many mechanisms…
Abstract Number: 2232 • 2019 ACR/ARP Annual Meeting
Results of the Implementation of a Bone Health Program in Patients with Rheumatoid Arthritis to Improve the Evaluation of Osteoporosis
Gabriel Figueroa-Parra¹, Rita Pineda-Sic ², Jairo Rodriguez-Hinojosa ³, Carmen Magdalena Gamboa-Alonso ⁴, Ana De-Leon-Ibarra ³, Janett Carmen Riega Torres ⁵, Iván de Jesús Hernández-Galarza ², Dionicio Galarza-Delgado ² and Cassandra Skinner Taylor ², ¹Universidad Autónoma de Nuevo León, "Hospital Universitario Dr. José Eleuterio González", Monterrey, Nuevo Leon, Mexico, ²Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Nuevo Leon, Mexico, ³Universidad Autónoma de Nuevo León, "Hospital Universitario Dr. José Eleuterio González", Monterrey, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁵Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr Jose Eleuterio Gonzalez", Monterrey, Mexico
Background/Purpose: Osteoporosis is a generalized skeletal disorder characterized by compromised bone strength and deterioration of quality, often leading to fragility fractures (1). People with rheumatoid…
Abstract Number: 956 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density Is a Causal Risk Factor for Knee and Hip Osteoarthritis: A Population-Based and Mendelian Randomization Study in the UK Biobank
Thomas Funck-Brentano¹, Maria Nethander², Sofia Moverare Skrtic¹, Pascal Richette³ and Claes Ohlsson¹, ¹Center for Bone and Arthritis Research, Department of Internal Medicine, Sahlgrensaka Academy, Gothenburg University, Gothenburg, Sweden, ²Bioinformatics Core Facility, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden, ³Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France
Background/Purpose: Osteoarthritis (OA) involves the whole joint, with alterations of cartilage, synovium and bone. Whether bone changes are a cause or consequence of the disease…
Abstract Number: 2639 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus
Tracy Driver¹, Maureen A. McMahon², Betty Tsao³ and Jennifer M. Grossman⁴, ¹Medicine, Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Osteoporosis is common in patients with systemic lupus erythematosus (SLE). Guidelines for the treatment and prevention of glucocorticoid induced osteoporosis (GIOP) are detailed for…
Abstract Number: 1257 • 2018 ACR/ARHP Annual Meeting
Simple and Cost-Effective Intervention Doubled the Rate of Osteoporosis Screening in High Risk Rheumatology Patients
Mosaab Mohameden¹, Victoria Malkhasyan², Adam Shurbaji¹ and Candice Yuvienco³, ¹Internal Medicine, University of California San Francisco - Fresno Medical Education Program, Fresno, CA, ²University of California San Francisco - Fresno Medical Education Program, Fresno, CA, ³Internal Medicine, Division of Rheumatology Director, University of California San Francisco - Fresno Medical Education Program, Division of Rheumatology Director, Fresno, CA
Background/Purpose: Osteoporosis is a common bone disorder that places patients at risk of pathologic fractures. Osteoporotic fractures can be devastating and associated with significant morbidity,…
Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting
T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial
Felicia Cosman¹, E. Michael Lewiecki², Peter R Ebeling³, Eric Hesse⁴, Nicola Napoli⁵, Daria B Crittenden⁶, Maria Rojeski⁶, Wenjing Yang⁶, Cesar Libanati⁷ and Serge Ferrari⁸, ¹Columbia University, New York, NY, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Monash University, Melbourne, Australia, ⁴University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Amgen Inc., Thousand Oaks, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Geneva University Hospital, Geneva, Switzerland
Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
Abstract Number: 1620 • 2018 ACR/ARHP Annual Meeting
Lateral DXA More Effective in Detecting Osteoporosis Than Conventional DXA in Axial Spondyloarthropathy
Gillian Fitzgerald^1,2, Jason Wyse³, Tochukwu Anachebe⁴, Ronan Mullan⁵, David Kane⁶, Kevin McCarroll⁷ and Finbar O' Shea², ¹School of Medicine, Trinity College Dublin, Dublin 2, Ireland, ²Rheumatology, St. James's Hospital, Dublin 8, Ireland, ³School of Computer Science and Statistics, Trinity College Dublin, Dublin 2, Ireland, ⁴Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland, ⁵Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ⁶Department of Rheumatology, Tallaght Hospital, TCD, Dublin 24, Ireland, ⁷Department of Medicine for the Elderly, St. James's Hospital, Dublin 8, Ireland
Background/Purpose: The severe consequences of osteoporosis in the general population are well outlined. In axial spondyloarthropathy (axSpA), osteoproliferation of the spine means posterioanterior (PA) dual-energy…
Abstract Number: 2810 • 2018 ACR/ARHP Annual Meeting
Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated with Abaloparatide Followed By Alendronate
Benjamin Leder¹, Carol Zapalowski², Ming-Yi Hu³ and Gary Hattersley², ¹Endocrine, Harvard Medical School, Boston, MA, ²Radius Health, Inc., Waltham, MA, ³Biometrics, Radius Health, Inc., Waltham, MA
Background/Purpose: Abaloparatide (ABL) is an anabolic PTHrP analog approved to treat postmenopausal women with osteoporosis at high risk of fracture. In the ACTIVE Phase 3…
Abstract Number: 1731 • 2018 ACR/ARHP Annual Meeting
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
Marine FAUNY¹, Elodie BAUER², Eliane ALBUISSON³, Julia Perrier-Cornet¹, Joelle DEIBENER⁴, Francois CHABOT⁵, Damien MANDRY⁶, Olivier HUTTIN⁷, Isabelle Chary-Valckenaere⁸ and Damien Loeuille², ¹Rheumatology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ²Rheumatology, University Hospital of Nancy, NANCY, France, ³University Hospital of Nancy, Nancy, France, ⁴Internal Medicine, University Hospital of Nancy, NANCY, France, ⁵Pneumology, University Hospital of Nancy, NANCY, France, ⁶Radiology, University Hospital of Nancy, NANCY, France, ⁷Cardiology, University Hospital of Nancy, NANCY, France, ⁸Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Osteoporosis screening is not systematic in sclerodermic patients but some studies demonstrated a similar risk between rheumatoid arthritis and systemic scleroderma [1,2,3]. Thoracic and/or…
Abstract Number: 2811 • 2018 ACR/ARHP Annual Meeting
Abaloparatide Effect on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis Aged 80 Years or Older
Susan L. Greenspan¹, Lorraine A Fitzpatrick², Bruce Mitlak², Yamei Wang², Nicholas C. Harvey³, Chad Deal⁴, Felicia Cosman⁵ and Michael McClung⁶, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Radius Health, Inc., Waltham, MA, ³MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom, ⁴Cleveland Clinic, Shaker Heights, OH, ⁵Columbia University College of Physicians and Surgeons, New York, NY, ⁶Oregon Osteoporosis Center, Portland, OR
Background/Purpose: The risk of fracture increases with increasing age. Thus, it is important to understand efficacy and safety of osteoporosis treatments in elderly patients. In…

« Previous Page
1
…
4
5
6
7
8
…
14
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].